Compare ARK Genomic Revolution ETF (ARKG) vs Microsoft (MSFT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Microsoft — how do they compare? ARK Genomic Revolution ETF trades at $40.95, while Microsoft trades at $387.55 (market cap $2.86T). The key difference: Microsoft pays a 0.95% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Microsoft nearer its low. Which is the better fit depends on your goals.
| ARKG | MSFT | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $542.07 |
52-Week Low | $23.09 | $352.83 |
Market Cap | — | $2.86T |
Volume | — | 36,654,621 |
Enterprise Value | — | $2.84T |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Microsoft (MSFT) trades at $385.10, up 0.19% on the day, with a bearish technical signal despite strong fundamentals. The company reported Q1 2026 EPS of $4.27, beating estimates, and maintains robust profitability with a 39.34% net income margin. Recent news highlights AI leadership and Azure momentum, though concerns over capital expenditures weigh on sentiment.
Outlook remains positive with an 80.49% analyst buy rating and a $548.87 consensus price target, implying significant upside. Risks include competitive pressures in AI, geopolitical tensions, and high valuation multiples. Long-term growth driven by cloud and AI investments supports a constructive view for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
